PMID- 32565132
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20231111
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Print)
IS  - 1465-3249 (Linking)
VI  - 22
IP  - 9
DP  - 2020 Sep
TI  - Emerging trends in COVID-19 treatment: learning from inflammatory conditions 
      associated with cellular therapies.
PG  - 474-481
LID - S1465-3249(20)30657-5 [pii]
LID - 10.1016/j.jcyt.2020.04.100 [doi]
AB  - Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which 
      treatments are desperately being sought. Even though most people infected 
      experience mild to moderate respiratory symptoms and recover with supportive 
      care, certain vulnerable hosts develop severe clinical deterioration. While 
      several drugs are currently being investigated in clinical trials, there are 
      currently no approved treatments or vaccines for COVID-19 and hence there is an 
      unmet need to explore additional therapeutic options. At least three inflammatory 
      disorders or syndromes associated with immune dysfunction have been described in 
      the context of cellular therapy. Specifically, Cytokine Release Syndrome (CRS), 
      Immune Reconstitution Inflammatory Syndrome (IRIS), and Secondary Hemophagocytic 
      Lymphohistiocytosis (sHLH) all have clinical and laboratory characteristics in 
      common with COVID19 and associated therapies that could be worth testing in the 
      context of clinical trials. Here we discuss these diseases, their management, and 
      potential applications of these treatment in the context of COVID-19. We also 
      discuss current cellular therapies that are being evaluated for the treatment of 
      COVID-19 and/or its associated symptoms.
CI  - Copyright (c) 2020 International Society for Cell and Gene Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Cancio, Maria
AU  - Cancio M
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic 
      address: Canciom@mskcc.org.
FAU - Ciccocioppo, Rachele
AU  - Ciccocioppo R
AD  - Department of Medicine, A.O.U.I Policlinico G.B Rossi and University of Verona, 
      Verona, Italy.
FAU - Rocco, Patricia R M
AU  - Rocco PRM
AD  - Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of 
      Biophysics, Federal university of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Levine, Bruce L
AU  - Levine BL
AD  - Center for Cellular Immunotherapies and Department of Pathology and Laboratory 
      Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Bronte, Vincenzo
AU  - Bronte V
AD  - Department of Medicine, A.O.U.I Policlinico G.B Rossi and University of Verona, 
      Verona, Italy.
FAU - Bollard, Catherine M
AU  - Bollard CM
AD  - Center for Cancer and Immunology Research, Center for Cancer and Blood Disorders, 
      Children's National Hospital and the George Washington University Cancer Center, 
      George Washington University, Washington, DC, USA.
FAU - Weiss, Daniel
AU  - Weiss D
AD  - University of Vermont Medical Center, Burlington, Vermont, USA.
FAU - Boelens, Jaap Jan
AU  - Boelens JJ
AD  - Memorial Sloan Kettering Cancer Center, New York, New York, USA.
FAU - Hanley, Patrick J
AU  - Hanley PJ
AD  - Center for Cancer and Immunology Research, Center for Cancer and Blood Disorders, 
      Children's National Hospital and the George Washington University Cancer Center, 
      George Washington University, Washington, DC, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200507
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 0 (STAT Transcription Factors)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - COVID-19
MH  - Coronavirus Infections/drug therapy/*etiology/physiopathology
MH  - Cytokine Release Syndrome/etiology/therapy
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/etiology/therapy
MH  - Immunization, Passive
MH  - Interleukin-1/antagonists & inhibitors
MH  - Interleukin-6/antagonists & inhibitors
MH  - Killer Cells, Natural/immunology
MH  - Lymphohistiocytosis, Hemophagocytic/etiology/therapy
MH  - Pandemics
MH  - Plasmapheresis
MH  - Pneumonia, Viral/*etiology/physiopathology
MH  - STAT Transcription Factors/antagonists & inhibitors
MH  - COVID-19 Drug Treatment
PMC - PMC7252029
OTO - NOTNLM
OT  - COVID-19
OT  - CRS
OT  - HLH
OT  - IRIS
OT  - SARS-CoV-2
OT  - cellular therapy
OT  - cytokine release
OT  - hyperimmune response
OT  - immunotherapy
EDAT- 2020/06/23 06:00
MHDA- 2020/09/08 06:00
PMCR- 2020/05/07
CRDT- 2020/06/23 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/04/29 00:00 [revised]
PHST- 2020/04/30 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/05/07 00:00 [pmc-release]
AID - S1465-3249(20)30657-5 [pii]
AID - 10.1016/j.jcyt.2020.04.100 [doi]
PST - ppublish
SO  - Cytotherapy. 2020 Sep;22(9):474-481. doi: 10.1016/j.jcyt.2020.04.100. Epub 2020 
      May 7.